TWELVE TWELVE GATEWAY

Brand Owner (click to sort) Address Description
1212 GATEWAY 1212 Gateway 331 Soquel Ave STE 207 Santa Cruz CA 95062 TWELVE TWELVE GATEWAY; ONE TWO ONE TWO GATEWAY; ONE THOUSAND TWELVE GATEWAY;Non-medicated skincare products, namely, facial toners, facial serums, facial gels, facial scrubs, exfoliant creams, face and body powders, hand cream, foot cream, body masks, non-medicated lip salves, body creams, body wash, body moisturizers, body lotions, body scrubs, body gels; and Cosmetics;
1212 GATEWAY 1212 Gateway 331 Soquel Ave STE 207 Santa Cruz CA 95062 TWELVE TWELVE GATEWAY; ONE TWO ONE TWO GATEWAY; ONE THOUSAND TWELVE GATEWAY;Non-medicated skincare products, namely, facial masks, facial cleansers, face wash, facial lotions, facial creams, facial moisturizers, facial oils, eye cream, lip masks, lip balms, body oils, body skin cleansers;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA), is administered topically to the surface of the affected eye at levels between 0.1 and 2,500 IU/ml, about eight to twelve times on the day of surgery, and four to eight times per day for about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1-1 IU uPA/ml, and also 1-10 IU/ml. Plasminogen activators that can be used in the inventions include urokinase, prourokinase, streptokinase and mutants thereof. The invention also covers topical ophthalmic compositions that include one or more plasminogen activators, most preferably uPA, to prevent or reduce postoperative corneal subepithelial haze.